An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Psoriasis
In brief
This is a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 will be administered to normal healthy volunteers (NHV) and to moderate to severe psoriatic patients, both in sequential ascending dose panels.
Key facts
- Study ID
- NCT02555709
- Run by
- Vitae Pharmaceuticals Inc., an Allergan affiliate
- People needed
- 74
- Starts
- 2015-08-01
- Expected to finish
- 2016-03-01
- Last updated by the study team
- 2018-10-30
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Patient Site 5 — Rogers, Arkansas, United States
- Patient Site 1 — Miami, Florida, United States
- Patient Site 8 — Tampa, Florida, United States
- Patient 12 — Tampa, Florida, United States
- Patient Site 13 — Carmel, Indiana, United States
- Patient Site 4 — Plainfield, Indiana, United States
- Healthy Volunteer Site 1 — Fair Lawn, New Jersey, United States
- Patient Site 2 — New York, New York, United States
- Patient Site 9 — High Point, North Carolina, United States
- Patient Site 6 — College Station, Texas, United States
- Patient Site 3 — Dallas, Texas, United States
- Patient Site 10 — Houston, Texas, United States
- Patient Site 11 — Houston, Texas, United States
- Patient Site 7 — Webster, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.